<DOC>
	<DOCNO>NCT00083135</DOCNO>
	<brief_summary>RATIONALE : Giving iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) may kill neuroblastoma cell deliver radiation directly tumor . A stem cell transplant use patient 's stem cell may able replace blood-forming cell destroy radiation therapy . PURPOSE : This phase I trial study side effect best dose double infusion ^131I-MIBG follow autologous stem cell transplantation treat patient refractory neuroblastoma .</brief_summary>
	<brief_title>N2000-01 : Double Infusion Iodine I 131 Metaiodobenzylguanidine Followed Autologous Stem Cell Transplantation</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine maximum tolerate red marrow radiation dose deliver associate toxic effect escalate activity iodine I 131 metaiodobenzylguanidine ( ^131I-MIBG ) follow autologous hematopoietic stem cell transplantation patient refractory neuroblastoma . - Determine number day stem cell transplantation achieve absolute neutrophil count ≥ 500/mm^3 3 day platelet count ≥ 20,000/mm^3 3 day ( without transfusion ) patient treat regimen . Secondary - Determine response rate patient treat regimen , base lesion measurable CT MRI study entry , patient ^131I-MIBG scan-positive lesion , patient minimal residual tumor bone marrow complete response immunocytology morphology . - Determine tumor absorb radiation dose patient measurable soft tissue lesion treat regimen . - Correlate , possible , TP53 mutation response patient accessible bone marrow tumor treat ^131I-MIBG . OUTLINE : This dose-escalation , multicenter study . - Iodine I 131 metaiodobenzylguanidine ( 131I-MIBG ) therapy : Patients receive^131I-MIBG IV 2 hour day 0 14 . Cohorts 3-6 patient receive escalate dos ^131I-MIBG maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . - Stem cell transplantation therapy : Patients undergo autologous peripheral blood stem cell transplantation day 28 . Patients receive filgrastim ( G-CSF ) IV 1 hour OR subcutaneously daily begin day 28 continue blood count recover . Patients follow every 3 month 1 year annually thereafter . PROJECTED ACCRUAL : A total 9-18 patient accrue study within 2 year .</detailed_description>
	<mesh_term>Neuroblastoma</mesh_term>
	<mesh_term>3-Iodobenzylguanidine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis neuroblastoma Confirmed least 1 follow method : Histology Clumps tumor cell bone marrow elevate urinary catecholamine metabolite Highrisk disease Poor response induction therapy OR relapse define follow : No response , stable disease , mixed response minimum 3 prior course chemotherapy More 100 tumor cell per 10^5 nucleated cell bone marrow immunocytology least 3 prior course chemotherapy Progressive disease time therapy Patients massive bone marrow invasion ( 50 % replacement bone marrow tumor cell ) allow Must positive iodine I 131 metaiodobenzylguanidine ( ^131IMIBG ) within past 6 week subsequent prior antitumor therapy deliver within past 6 week Must meet follow criterion minimum number autologous stem cell : Unpurged peripheral blood stem cell ( PBSC ) Minimum 1,500,000/mm^3 CD34positive cells/kg Collected product must &lt; 1 tumor cell/100,000 normal cell immunocytology PBSC purge immunomagnetic bead Minimum 1,000,000/mm^3 viable CD34positive cells/kg Collected product must &lt; 1 tumor cell/100,000 normal cell immunocytology CD34positive select PBSC product allow Patients PBSC collect previously immunocytological test available may use product provide bone marrow tumor free bilateral bone marrow aspirate AND biopsy morphology perform within 4 week PBSC collection Patients tumor involvement bone marrow diagnosis PBSC collection disease progression require documentation negative bone marrow morphology PATIENT CHARACTERISTICS : Age 1 30 Performance status ECOG 02 Life expectancy Less 1 year Hematopoietic Absolute neutrophil count ≥ 500/mm^3 Platelet count ≥ 50,000/mm^3 ( without transfusion ) Hemoglobin ≥ 8 g/dL ( transfusion allow ) Hepatic AST ALT ≤ 5 time normal Bilirubin &lt; 2 time normal Renal Creatinine ≤ 1.5 mg/dL Glomerular filtration rate OR 12hour creatinine clearance ≥ 60 mL/min/1.73m^2 Cardiovascular Ejection fraction ≥ 55 % echocardiogram MUGA OR Fractional shorten ≥ 30 % OR low limit normal echocardiogram Pulmonary Normal lung function No dyspnea rest No exercise intolerance No oxygen requirement Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able cooperate physically psychologically radiation isolation No disease major organ system would preclude study participation No active infection require antiviral , antibiotic , antifungals No weight would require exceed maximum total allowable dose ^131IMIBG PRIOR CONCURRENT THERAPY : Biologic therapy At least 2 week since prior biologic nonmyelosuppressive therapy Chemotherapy See Disease Characteristics At least 2 week since prior chemotherapy More 3 month since prior myeloablative therapy Endocrine therapy Not specify Radiotherapy See Disease Characteristics At least 6 month since prior craniospinal , total abdominal , whole lung radiotherapy At least 2 week since prior radiotherapy site No prior total body irradiation No prior radiotherapy &gt; 25 % bone marrow No prior ^131IMIBG Surgery Not specify Other Recovered prior therapy Concurrent antifungal therapy allow provided culture biopsy negative suspect radiographic lesion Prior reinduction therapy recurrent tumor allow No concurrent antiretroviral therapy HIVpositive patient No concurrent hemodialysis</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>May 2009</verification_date>
	<keyword>recurrent neuroblastoma</keyword>
</DOC>